Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

3.

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV.

J Thorac Oncol. 2010 Nov;5(11):1855-8. doi: 10.1097/JTO.0b013e3181f0bee0.

4.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930.

PMID:
19414683
5.

The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected].

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O.

Anticancer Res. 2014 Sep;34(9):5193-8. Erratum in: Anticancer Res. 2014 Nov;34(11):6859. Anticancer Res. 2014 Dec;34(12):7485.

PMID:
25202114
6.

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).

Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.

Anticancer Res. 2015 Jul;35(7):3885-91.

PMID:
26124334
7.

[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Fan Y, Huang ZY, Yu HF, Luo LH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Chinese.

PMID:
21223694
8.

[Clinical developments for the EGFR-TKI combined with radiotherapy in advanced non-small cell lung cancer].

Li X, Zhu G.

Zhongguo Fei Ai Za Zhi. 2014 Apr;17(4):357-62. doi: 10.3779/j.issn.1009-3419.2014.04.12. Review. Chinese.

9.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Review.

PMID:
21435938
10.

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R.

Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008.

PMID:
20705357
11.

[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].

Tang C, Li X, Guo W, Li J, Qin H, Wang W, Qu L, An J, Gao H, Liu X.

Zhongguo Fei Ai Za Zhi. 2013 Jul;16(7):345-52. doi: 10.3779/j.issn.1009-3419.2013.07.03. Chinese.

12.

Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.

Imai H, Shukuya T, Takahashi T, Fujiwara S, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Harada H, Endo M, Nakajima T, Yamamoto N.

Anticancer Res. 2013 Aug;33(8):3279-84.

PMID:
23898092
13.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357.

14.

Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.

Yang L, Tang C, Xu B, Wang W, Li J, Li X, Qin H, Gao H, He K, Song S, Liu X.

PLoS One. 2015 Jun 5;10(6):e0128970. doi: 10.1371/journal.pone.0128970.

15.

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF.

Lung Cancer. 2014 Jul;85(1):19-24. doi: 10.1016/j.lungcan.2014.03.016.

PMID:
24768581
16.

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.

Becker A, Crombag L, Heideman DA, Thunnissen FB, van Wijk AW, Postmus PE, Smit EF.

Eur J Cancer. 2011 Nov;47(17):2603-6. doi: 10.1016/j.ejca.2011.06.046.

PMID:
21784628
17.

Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.

Kuo CH, Lin SM, Lee KY, Chung FT, Hsieh MH, Fang YF, Yu CT, Kuo HP.

Clin Lung Cancer. 2010 Jan;11(1):51-6. doi: 10.3816/CLC.2010.n.008.

PMID:
20085868
18.

Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.

Umekawa K, Kimura T, Kudoh S, Suzumura T, Nagata M, Mitsuoka S, Matsuura K, Oka T, Yoshimura N, Kira Y, Hirata K.

Osaka City Med J. 2013 Jun;59(1):53-60.

PMID:
23909081
19.

Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.

Hsiao SH, Liu HE, Lee HL, Lin CL, Chen WY, Wu ZH, Lin SE, Chiang LL, Chung CL.

PLoS One. 2013 Dec 23;8(12):e83266. doi: 10.1371/journal.pone.0083266.

20.

A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA.

Lung Cancer. 2006 Jan;51(1):115-21.

PMID:
16188343

Supplemental Content

Support Center